Bringing the world’s first insect vaccine from discovery to commercial reality marks a defining milestone for Dalan Animal Health. Annette Kleiser, CEO, shares how Dalan is now applying its innate immunity platform to aquaculture, advancing proof-of-concept in shrimp, and exploring broader species application.

Approval alone doesn’t guarantee commercial success. Robert Jordan shares how Vetirus Pharmaceuticals combines in-house regulatory expertise with early manufacturing planning, ensuring supply, shortening timelines to revenue, and enabling global expansion.

Scaling beyond limited early-stage momentum often calls for a disciplined corporate turnaround strategy. Jake Burlet outlines the practical steps CanBiocin took to shift from grant-to-grant R&D survival to a profitable growing enterprise through securing strategic investment.

Commercialising a new category of care requires more than product innovation. Rebecca Windsor, Director of Veterinary Affairs at Gallant, shares how education and developing trusted continuing education platforms have been central to preparing veterinarians for the clinical adoption of regenerative medicine.

Evolving pet owner expectations demand new models of engagement. Susan Groeneveld shares how Sylvester.AI is pioneering direct-to-consumer pathways to connect with owners, strengthen veterinary partnerships, and unlock commercial scale. 

Securing non-dilutive capital can be the key to bridging the gap between research and commercial reality for agtech startups. Matt Dobbs shares how AgSenze leveraged grant programmes including Innovate UK and EU Horizon to de-risk R&D, unlock private investment, and provide a launchpad of scaling HerdVision.